Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Heparin in PCI (ISAR-REACT-3A)
NCT00735280Phase 4Completed
- Sponsor
- Deutsches Herzzentrum München
- Start
- Aug 2008
- Primary completion
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of heparin in coronary artery disease (CAD), sponsored by Deutsches Herzzentrum München. Primary endpoint: Composite of death, myocardial infarction, urgent target vessel revascularization, or in-hospital major bleeding at 30 days. Started Aug 2008; status: completed.
02
Drugs
heparin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00735280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00735280.